← Trials/Trial dossier/NCT05762744
Pharmacogenomics of GLP1 Receptor Agonists
Lead sponsor
Assets
Exenatide / GLP-1 / incretin class catch-all
Listed sites
1
Recruiting sites
—
Enrollment
63
actual
Study population
Healthy volunteers
Key I/E criterion
•BMI 18-40
Primary endpoints
•Exenatide Effect on First Phase Insulin Secretion•Exenatide Effect on Glucose Disappearance Rate
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (16)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Glycemic / diabetes
16 endpointsExenatide Effect on First Phase Insulin Secretion
Time frame:0-10 minutes
descriptive
Posted result
| Group | Value (mean), Ratio (no units) | 95% CI |
|---|---|---|
| Exenatide First Followed by Saline | 1.90 | — |
| Saline First Followed by Exenatide | 2.18 | — |
Null hypothesis: the order of FSIGTs (saline or exenatide-stimulated) does not affect the response during an FSIGT
Exenatide Effect on Glucose Disappearance Rate
Time frame:25-50 minutes
descriptive
Posted result
| Group | Value (mean), Ratio (no units) | 95% CI |
|---|---|---|
| Exenatide First Followed by Saline | 2.16 | — |
| Saline First Followed by Exenatide | 2.28 | — |
Null hypothesis: The order of FSIGT (exenatide-stimulated or saline) does not affect the response to an FSIGT.
Exenatide Effect on First Phase Insulin Secretion
Time frame:0-10 minutes
ratio, improvement
Exenatide Effect on Glucose Disappearance Rate
Time frame:25-50 minutes
ratio, improvement
Glucose Disappearance Rate (Exenatide)
Time frame:25-50 minutes
descriptive
Posted result
| Group | Value (mean), Log(mg/dL) per min | 95% CI |
|---|---|---|
| Exenatide First Followed by Saline | 1056 | — |
| Saline First Followed by Exenatide | 1131 | — |
Null hypothesis: the order of testing (exenatide-stimulated or saline FSIGT) does not affect data obtained in the FSIGTs.
Glucose Disappearance Rate (Placebo)
Time frame:25-50 minutes
descriptive
Posted result
| Group | Value (mean), Log(mg/dL) per min | 95% CI |
|---|---|---|
| Exenatide First Followed by Saline | 500 | — |
| Saline First Followed by Exenatide | 547 | — |
The order of FSIGTs (exenatide-stimulated or saline) does not affect the response during an FSIGT
First Phase Insulin Secretion (Exenatide)
Time frame:0-10 minutes
descriptive
Posted result
| Group | Value (mean), microunits/mL*min | 95% CI |
|---|---|---|
| Exenatide First Followed by Saline | 561 | — |
| Saline Followed by Exenatide | 494 | — |
Null hypothesis: the order of FSIGT (exenatide or saline) does not affect the response during an FSIGT
First Phase Insulin Secretion (Placebo)
Time frame:0-10 minutes
descriptive
Posted result
| Group | Value (mean), microunits/mL*min | 95% CI |
|---|---|---|
| Exenatide First Followed by Normal Saline | 305 | — |
| Placebo First Followed by Exenatide | 254 | — |
Null hypothesis: The order of FSIGTs (exenatide-stimulated or saline) does not affect the response to an FSIGT
Drug Effect on First-Phase Insulin Secretion (Genotype-specific)
Time frame:0 - 10 min during the FSIGT
descriptive
Posted result
| Group | Value (mean), Ratio: no units | 95% CI |
|---|---|---|
| Major Allele Homozygotes | 2.25 | — |
| Homozygotes for the p.G40S Allele of GCGR | 1.94 | — |
| Homozygotes for the p.E354Q Allele of GIPR | 1.87 | — |
Null hypothesis: no differences between the two groups with respect to exenatide's effect on first-phase insulin secretion. t-test conducted on logarithms of the values
Null hypothesis: no difference between two groups with respect to exenatide's effect on first phase insulin secretion
Exenatide's Effect on the Rate of Glucose-disappearance (Genotype Specific)
Time frame:25-50 min during the FSIGT
descriptive
Posted result
| Group | Value (mean), Log(mg/dL) per min | 95% CI |
|---|---|---|
| Major Allele Homozygotes | 2.19 | — |
| Homozygotes for the p.G40S Allele of GCGR | 2.28 | — |
| Homozygotes for the p.E354Q Allele of GIPR | 2.18 | — |
Null hypothesis: the two genotype groups do not differ with respect to the effect of exenatide on the rate of glucose disappearance
Null hypothesis: the two genotype groups do not differ with respect to the effect of exenatide on the rate of glucose disappearance during an FSIGT
Glucose Disappearance Rate (Exenatide)
Time frame:25-50 minutes
descriptive
Glucose Disappearance Rate (Placebo)
Time frame:25-50 minutes
descriptive
First Phase Insulin Secretion (Exenatide)
Time frame:0-10 minutes
concentration, descriptive
First Phase Insulin Secretion (Placebo)
Time frame:0-10 minutes
concentration, descriptive
Drug Effect on First-Phase Insulin Secretion (Genotype-specific)
Time frame:0 - 10 min during the FSIGT
ratio, improvement
Exenatide's Effect on the Rate of Glucose-disappearance (Genotype Specific)
Time frame:25-50 min during the FSIGT
descriptive
Publications (2)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- Clinical and translational science2024 May (month)PMID38700326doi:10.1111/cts.13809via clinicaltrials gov reference derived + pubmed nct search
- Diabetes, obesity & metabolism2023 Sep (month)PMID37264484doi:10.1111/dom.15143via CT.gov background + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.